全文获取类型
收费全文 | 24933篇 |
免费 | 2355篇 |
国内免费 | 1686篇 |
专业分类
耳鼻咽喉 | 221篇 |
儿科学 | 370篇 |
妇产科学 | 279篇 |
基础医学 | 2790篇 |
口腔科学 | 452篇 |
临床医学 | 3173篇 |
内科学 | 3751篇 |
皮肤病学 | 300篇 |
神经病学 | 1323篇 |
特种医学 | 890篇 |
外国民族医学 | 13篇 |
外科学 | 2582篇 |
综合类 | 4434篇 |
现状与发展 | 6篇 |
一般理论 | 6篇 |
预防医学 | 1851篇 |
眼科学 | 629篇 |
药学 | 2442篇 |
25篇 | |
中国医学 | 1566篇 |
肿瘤学 | 1871篇 |
出版年
2024年 | 98篇 |
2023年 | 394篇 |
2022年 | 1028篇 |
2021年 | 1286篇 |
2020年 | 924篇 |
2019年 | 779篇 |
2018年 | 837篇 |
2017年 | 717篇 |
2016年 | 697篇 |
2015年 | 1012篇 |
2014年 | 1179篇 |
2013年 | 1203篇 |
2012年 | 1836篇 |
2011年 | 1888篇 |
2010年 | 1314篇 |
2009年 | 1115篇 |
2008年 | 1441篇 |
2007年 | 1410篇 |
2006年 | 1423篇 |
2005年 | 1234篇 |
2004年 | 972篇 |
2003年 | 980篇 |
2002年 | 850篇 |
2001年 | 662篇 |
2000年 | 656篇 |
1999年 | 545篇 |
1998年 | 329篇 |
1997年 | 289篇 |
1996年 | 233篇 |
1995年 | 247篇 |
1994年 | 191篇 |
1993年 | 110篇 |
1992年 | 179篇 |
1991年 | 153篇 |
1990年 | 111篇 |
1989年 | 95篇 |
1988年 | 100篇 |
1987年 | 84篇 |
1986年 | 67篇 |
1985年 | 57篇 |
1984年 | 37篇 |
1983年 | 27篇 |
1982年 | 19篇 |
1981年 | 17篇 |
1980年 | 18篇 |
1979年 | 31篇 |
1977年 | 16篇 |
1973年 | 11篇 |
1972年 | 10篇 |
1971年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
妊娠高血压综合征患者血清sICAM-1含量测定及其在妊高征发病中的作用 总被引:2,自引:0,他引:2
目的 探讨可溶性细胞间粘附分子 1(soluble intercellular adhesion molecule- 1,s ICAM- 1)在妊娠高血压综合征 (简称妊高征 )发病中的作用。 方法 应用酶联免疫吸附法 (EL ISA)测定 6 5例妊高征患者 (妊高征组 ,包括轻度 15例 ,中度 2 4例 ,重度 2 6例 )及 2 5例同期正常妊娠孕妇(对照组 )外周血清中 s ICAM- 1的含量 ;应用化学发光酶联免疫分析法测定两组孕妇血清中白细胞介素 1(interleukin- 1,L I- 1β)及肿瘤坏死因子 (tum or necrosing factor alpha,TNF- α)含量 ;并记录新生儿体重及妊娠结局。 结果 轻、中、重度妊高征组母血清中 s ICAM- 1的含量 [(36 8.5 6± 6 2 .81) μg/L、(6 0 6 .6 3± 10 5 .0 4 ) μg/ L、(85 9.36± 2 0 0 .92 ) μg/ L]均显著高于对照组 [(2 36 .6 9± 96 .33) μg/ L](P<0 .0 5 ,P<0 .0 1,P<0 .0 1) ,中、重度妊高征组母血清中 IL- 1β及 TNF- α的含量均显著高于对照组(P<0 .0 5 ,P<0 .0 1) ;中、重度妊高征组 s ICAM- 1的水平与相应 IL- 1β及 TNF- α的水平呈显著的正相关 (r=0 .6 97,P<0 .0 1;r=0 .74 6 ,P<0 .0 1)。重度妊高征组伴胎儿生长受限 (fetal growth restric-tion,FGR)者血中 s ICAM- 1含量显著高于同组其他孕妇之含量 (P<0 .0 5 )。妊高征组 相似文献
54.
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. 总被引:1,自引:0,他引:1
Nam H Dang Fredrick B Hagemeister Barbara Pro Peter McLaughlin Jorge E Romaguera Dan Jones Barry Samuels Felipe Samaniego Anas Younes Michael Wang Andre Goy Maria A Rodriguez Pamela L Walker Yolanda Arredondo Ann T Tong Luis Fayad 《Journal of clinical oncology》2004,22(20):4095-4102
PURPOSE: Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells expressing the IL-2 receptor. Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin's lymphoma (NHL). A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL. PATIENTS AND METHODS: Patients with relapsed or refractory B-cell NHL were eligible. Tumor CD25 expression was determined by immunohistochemistry or flow cytometry. Denileukin diftitox was administered intravenously at a dose of 18 microg/kg once daily for 5 days every 3 weeks, up to eight cycles. RESULTS: Of the 45 patients assessable for response, 32 (71%) were refractory to the last chemotherapy treatment, and all were previously treated with rituximab. Three complete responses (6.7%) and eight partial responses (17.8%) were observed, for an overall response rate of 24.5%. Nine patients (20%) had stable disease. Objective response rates were similar in CD25+ (22%) and CD25- histologies (29%), as were stable disease rates (22% and 18%, respectively). For responding patients, the median time to treatment failure was 7 months, with a median follow-up in survivors of 18 months (range, 9 to 28 months), and the projected progression-free survival at 20 months was 24% (95% CI, 0% to 60%). Most toxicities were low-grade and transient. CONCLUSION: Denileukin diftitox seems to be effective in relapsed or refractory, CD25+ and CD25- B-cell NHL and is well-tolerated at the dosage evaluated. Evaluation of denileukin diftitox in combination with other agents may be warranted. 相似文献
55.
56.
57.
异基因造血干细胞移植并发致死性间质性肺炎 总被引:3,自引:0,他引:3
目的探讨小儿异基因造血于细胞移植并发间质性肺炎(IP)的发病病因、临床特点、危险因素及防治措施。方法根据尸解病理检查及聚合酶键反应技术对病毒病原学检测结果,结合临床移植资料综合分析。结果14例移植患儿中并发IP3例(3/14),分别死于十19天、+76天、+150天;3例IP中2例移植前后外周血及尸解肺组织直到CMV包涵体;4例3~4应急性GVHD患儿中3例并发IP,10例0~2度急性GVHD无1例并发IP。结论IP是移植早期死亡的重要原因之一,巨细胞病毒感染是IP的主要病原,GVHD严重程度与移植后并发IP密切相关. 相似文献
58.
Karl T. Kelsey Margaret R. Spitz Zheng-Fa Zuo John K. Wiencke 《Cancer causes & control : CCC》1997,8(4):554-559
The genes coding for separate isoforms of both the human glutathioneS-transferase class mu and class theta enzymes (GSTM1and GSTT1) arepolymorphic with a variable ethnic distribution. These enzymes detoxifyreactive epoxides, including carcinogens produced by tobacco smoke. Becauseof this, the null polymorphism in the GSTM1 gene (coding for the glutathioneS-transferase class mu enzyme) has been studied widely as a possible sourceof inherited susceptibility to smoking-related lung cancer. The more recentlydescribed null polymorphism in the GSTT1 gene also could contribute to anincreased risk of smoking-related lung cancer. As the incidence of lungcancer is known to differ by ethnicity, we have conducted a case-controlstudy in the United States of 108 African-Americans (Blacks) and 60Mexican-Americans (Hispanics) with lung cancer and 132 African-American(Black) and 146 Mexican-American (Hispanic) controls to investigate theassociation of the GSTT1 and GSTM1 polymorphi sms with lung cancer inminority populations. In the unadjusted data, there was a borderlinesignificant association of the GSTM1 null polymorphism with lung cancer inMexican-Americans (odds ratio [OR] = 1.8, 95 percent confidence interval [CI]= 1.0-3.3 ) that was not observed in African-Americans. The GSTT1 nullpolymorphism also had a higher prevalence in cases than controls in bothracial/ethnic groups, but this increase was not statistically significant.When the data were analyzed using logistic regression controlling for age,gender, race, and smoking, no significant association of either trait withlung cancer was observed, with ORs for both traits of approximately 1.3.However, when the prevalence of individuals who were null for bothpolymorphisms was compared by case status, a significant interaction wasobserved. Logistic regression models showed the OR for the association oflung cancer and the presence of both null polymorphisms compared with one(either GSTT1 or GSTM1) or no null genotype to be 2.9 (P < 0.04). Theseresults suggest that there may be carcinogenic intermediates in cigarettesmoke that are substrates for both the GSTT1 and GSTM1 enzymes, and that lungcancer risk is increased more than additively for individuals who have bothGSTT1 and GSTM1 null polymorphisms. 相似文献
59.
肾上腺素诱导兔血小板聚集的实践与理论探讨 总被引:1,自引:0,他引:1
目的创建以Adr诱导兔血小板聚集的方法,并对受体分子特性作初步探讨。方法以高K+缓冲液等取代兔PRP中血浆,以Adr诱导聚集,以Apyr证实结果。结果兔血小板悬浮于高K+缓冲液时Adr能单独诱导真正的聚集。结论由此推测血小板膜上α2肾上腺素受体分子可能为由两种亚单位组成:促聚亚单位和辅助亚单位。人辅助亚单位当Adr浓度高达聚集阈值以上时可被激活,与促聚亚单位结合为活性的二聚体,与Adr进一步结合发生聚集作用。兔辅助亚单位则还需要高K+方能被激活 相似文献
60.
OBJECTIVE: To assess the effect of middle turbinate (MT) and ethmoidal internal wall(EIW) moved externally after microsurgery. METHODS: Twenty-four cases (45 sides) were followed-up endoscopically for (16.3 +/- 9.3) months. Thirteen cases (24 sides) were observed by CT scans. Three cadaver heads were measured for anatomical analysis. RESULTS: Forty-one (91%) of 45 sides obtained better olfactory function after operation. Twenty-two (91%) of 24 sides were found to have better CT changes in sinus ventilation as compared with preoperative CT scans. The gap between the MT and EIW to the orbital wall was (12.0 +/- 1.0) mm, while that between the ethmoidal bulla and processus uncinatus was only (2.3 +/- 0.6) mm as revealed in the autopsy. CONCLUSION: MT and EIW moderately moved suitably to externally had no bad effect on sinus ventilation, and it improved olfaction. 相似文献